Table 3.

Continuous data synthesis of clinical and hormonal outcomes before and after treatment in 9 studies, for which raw data values were available (19, 21-24, 26, 27, 33, 34)

OutcomePretreatment (mean ± SD)Posttreatment (mean ± SD)PAdjusted Pa
Testicular volume, mL0.35 ± 0.30 (n = 12)1.29 ± 0.81 (n = 17).0007.0049
Stretched penile length, mm17.71 ± 5.37 (n = 24)36.54 ± 11.36 (n = 24)<.0001.0007
LH, IU/Lb0.05 (0.11) (n = 17)2.45 (3.38) (n = 12)<.0001.0007
FSH, IU/L0.30 ± 0.31 (n = 18)17.83 ± 18.37 (n = 15).0003.0021
Testosterone, nmol/L0.14 ± 0.07 (n = 25)7.73 ± 8.89 (n = 14).0001.0007
Inhibin B, pg/mL71.42 ± 44.64 (n = 18)275.00 ± 166.50 (n = 17)<.0001.0007
AMH, pmol/L694.50 ± 579.90 (n = 11)1067.00 ± 852.20 (n = 10).2516.8685
OutcomePretreatment (mean ± SD)Posttreatment (mean ± SD)PAdjusted Pa
Testicular volume, mL0.35 ± 0.30 (n = 12)1.29 ± 0.81 (n = 17).0007.0049
Stretched penile length, mm17.71 ± 5.37 (n = 24)36.54 ± 11.36 (n = 24)<.0001.0007
LH, IU/Lb0.05 (0.11) (n = 17)2.45 (3.38) (n = 12)<.0001.0007
FSH, IU/L0.30 ± 0.31 (n = 18)17.83 ± 18.37 (n = 15).0003.0021
Testosterone, nmol/L0.14 ± 0.07 (n = 25)7.73 ± 8.89 (n = 14).0001.0007
Inhibin B, pg/mL71.42 ± 44.64 (n = 18)275.00 ± 166.50 (n = 17)<.0001.0007
AMH, pmol/L694.50 ± 579.90 (n = 11)1067.00 ± 852.20 (n = 10).2516.8685

Data pass normality testing using the Shapiro-Wilk test and are represented by mean and SD. Sample size is shown in parentheses for each data synthesis. P values generated using an unpaired t test. Statistical significance is taken at P less than .0014.

Abbreviations: AMH, antimüllerian hormone; FSH, follicle-stimulating hormone; LH, luteinizing hormone.

aPost Bonferroni adjustment.

bNonparametric data shown as median (interquartile range).

Table 3.

Continuous data synthesis of clinical and hormonal outcomes before and after treatment in 9 studies, for which raw data values were available (19, 21-24, 26, 27, 33, 34)

OutcomePretreatment (mean ± SD)Posttreatment (mean ± SD)PAdjusted Pa
Testicular volume, mL0.35 ± 0.30 (n = 12)1.29 ± 0.81 (n = 17).0007.0049
Stretched penile length, mm17.71 ± 5.37 (n = 24)36.54 ± 11.36 (n = 24)<.0001.0007
LH, IU/Lb0.05 (0.11) (n = 17)2.45 (3.38) (n = 12)<.0001.0007
FSH, IU/L0.30 ± 0.31 (n = 18)17.83 ± 18.37 (n = 15).0003.0021
Testosterone, nmol/L0.14 ± 0.07 (n = 25)7.73 ± 8.89 (n = 14).0001.0007
Inhibin B, pg/mL71.42 ± 44.64 (n = 18)275.00 ± 166.50 (n = 17)<.0001.0007
AMH, pmol/L694.50 ± 579.90 (n = 11)1067.00 ± 852.20 (n = 10).2516.8685
OutcomePretreatment (mean ± SD)Posttreatment (mean ± SD)PAdjusted Pa
Testicular volume, mL0.35 ± 0.30 (n = 12)1.29 ± 0.81 (n = 17).0007.0049
Stretched penile length, mm17.71 ± 5.37 (n = 24)36.54 ± 11.36 (n = 24)<.0001.0007
LH, IU/Lb0.05 (0.11) (n = 17)2.45 (3.38) (n = 12)<.0001.0007
FSH, IU/L0.30 ± 0.31 (n = 18)17.83 ± 18.37 (n = 15).0003.0021
Testosterone, nmol/L0.14 ± 0.07 (n = 25)7.73 ± 8.89 (n = 14).0001.0007
Inhibin B, pg/mL71.42 ± 44.64 (n = 18)275.00 ± 166.50 (n = 17)<.0001.0007
AMH, pmol/L694.50 ± 579.90 (n = 11)1067.00 ± 852.20 (n = 10).2516.8685

Data pass normality testing using the Shapiro-Wilk test and are represented by mean and SD. Sample size is shown in parentheses for each data synthesis. P values generated using an unpaired t test. Statistical significance is taken at P less than .0014.

Abbreviations: AMH, antimüllerian hormone; FSH, follicle-stimulating hormone; LH, luteinizing hormone.

aPost Bonferroni adjustment.

bNonparametric data shown as median (interquartile range).

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close